e development of pharmaceutical agents reducing gastric acidity such as sucralfate, histamine 2 (H2) receptor blockers, and proton pump inhibitors (PPIs) has been a milestone for the treatment of dyspeptic disorders. However, due to current prescription habits resulting in overuse of these potent drugs as well as over-the-counter (OTC) availability associated with self-medication, substantial health concern is related to the mechanisms of drug action as well as known side e ects in uencing gastrointestinal physiology. More than a decade ago, the rst study appeared reporting an association between anti-ulcer drug intake and food allergy development. Since then, several experimental and human studies veri ed this correlation, demonstrating that acid suppressive drugs not only in uence the sensitization capacity of orally ingested proteins, but also represent a risk factor for food allergic patients. Additionally, gastric acid suppression was reported to increase the risk for development of drug hypersensitivity reactions. ese consequences of anti-ulcer drug intake might on the one hand be associated with direct in uence of these drugs on immune responses. On the other hand reduction of gastric acidity leads to impaired gastrointestinal protein degradation. Nevertheless, also disruption of the gastrointestinal barrier function, changes in microbiome, or lack of tolerogenic peptic digests might contribute to the connection between anti-ulcer drug intake and allergic reaction. erefore, these drugs should only be prescribed based on a precise gastroenterological diagnosis taking into consideration allergological mechanisms to ensure patients' safety.
Introduction
Until the 1970s, treatment of diseases associated with inadequate gastric acid secretion was limited to the use of antacids neutralizing excessive gastric acid and partial surgical elimination of the stomach. As this treatment was associated with insu cient mucosal healing and as surgical interventions expectably had severe side e ects, e ective pharmacological control of gastric acid secretion was a desirable goal of pharmaceutical research. In 1972, the rst H2 receptor blocker buimamide was developed. is major pharmaceutical break-through was followed by development of the widely prescribed H2 receptor antagonist cimetidine in 1975 [1] . e major advantage of both compounds was direct interference with the acid stimulating capacity of histamine via its receptor on parietal cells.
Only a few years later, rst studies on the ulcer-healing and pepsin-binding properties of the basic aluminum sucrose sulfate complex termed sucralfate were published and this drug class was approved for the treatment of acute ulcers as well as continuous maintenance therapy for disease recurrence prevention [2, 3] .
In parallel, pharmaceutical companies continued their e orts to develop novel therapeutics to reduce gastric acid output. In 1988, the PPI omeprazole was approved in Europe, followed by marketing of the same compound two years later in the US [4] . is and other drugs with proton pump inhibitory action being subsequently released were quickly accepted as clinically superior to previous antisecretory medication [5] .
Besides their substantial bene t for management of patients with dyspeptic disorders, gastric acid suppressive drugs can be considered a goldmine for the pharmaceutical industry. Even at the end of the patent protection period, the PPI esomeprazole is still among the top selling drugs worldwide and the rst PPIs on the market omeprazole and esomeprazole were recently ranked among the all-time best selling drugs [6, 7] . Besides an indicated long term use of this medication for relapse prevention in case of gastro-esophageal re ux (GERD), re ux esophagitis, and non-erosive re ux disease (NERD) [8] , there is substantial health and economical concern about overuse and the inadequate prescription habits of acid suppression drugs. Several studies revealed that around 70 % of patients admitted to nursing facilities or being hospitalized were on acid suppressive medication with more than 50 % of them without an appropriate diagnosis justifying prescription [9, 10] . Another major health concern is the current inappropriate self-medication habit. Approximately 80 % of patients with dyspeptic disorders of minor severity do not seek medical advice and simply use OTC available acid suppressive drugs [11] .
Mechanisms of action and side e ects of anti-ulcer drugs
From a chemical point of view, antacids are weak bases, such as hydroxides or carbonates, used to neutralize hydrochloric acid in the stomach [12] .
ey are formulated as salts of an alkaline ion in combination with one polyvalent cation such as calcium, aluminum, and magnesium. Even though they are rarely prescribed by physicians, antacids are frequently used without prescription due to OTC availability. Major concerns regarding safety of these drugs are the observed pH-dependent or chelation-dependent drug interactions [13] .
Being a derivative of aluminum hydroxide containing antacids, sucralfate is a salt of sucrose sulfate and aluminum hydroxide.
e drug was demonstrated to be activated in the presence of acidity. Upon release of aluminum, the molecule obtains a negative charge interacting with positively charged chemical groups in its environment such as H + ions, drugs, or mucins. It is known for its pepsin binding capacity, thereby reducing pepsin concentration in gastric juices [14, 15] . Moreover, sucralfate has a mucosal protective e ect by forming a physical barrier in the form of complex gels and interacts with high a nity with normal as well as inamed mucosa [16, 17, 18] . In post-marketing evaluations, sucralfate was described as an e cient and safe drug with limited side e ects [19, 20] with obstipation reported as the most common undesired e ect occurring in up to 15 % of patients [16, 21] .
As histamine has an acid secretion activation function via its H2 receptor on parietal cells, interference with this receptor by antagonists was the rst available causative treatment option for dyspeptic disorders. Later it was found that the acid secretion antagonizing e ect of H2 receptor blockers is not only due to inhibition of histamine stimulation, but also due to interference with carbachol and gastrin stimulation, both acting via H2 receptors [22] . Regarding side e ects of these drugs, the initial fear of many physicians was predisposition to bacterial overgrowth and consequently elevated intra gastric levels of N-nitrosoamine, a known carcinogen. However, long-term clinical experience proofed these drugs not to harbor cancer inducing properties [23] . Regarding bacterial overgrowth and infections, these drugs seem to pose a minor risk compared to PPIs as reviewed below, probably due to the observed circadian changes in acid control by H2 receptor blockers [22] . Nevertheless, it is well accepted that H2 receptor blockers strongly interfere with cytochrome P450 (CYP450) enzymes, which requires special caution regarding interaction with other pharmaceuticals [24] .
PPIs were designed to acquire their potential acid suppressive function via speci c and irreversible inhibition of the H + ,K + -ATPase located in the secretory membrane of the parietal cells [25] [26] [27] . In uencing function and bioavailability, di erent PPI subclasses revealed not only variations in speed and degree of gastric acid reduction but also in metabolism by hepatic CYP450 enzymes [28] . One side e ect of PPIs and other acid-reducing drugs is the lowered bioavailability of drugs depending on acidic intragastric pH for absorption. 
Impact of anti-ulcer drugs on function of the gastrointestinal tract
As indicated above, acid-reducing medication either binds protons in the gastric lumen or substantially reduces the gastric acid output, which is the therapeutic goal for the treatment of acid related disorders. Acidity itself is not only required for protection against infectious agents. Acidity also initiates protein degradation by in uencing food proteinfood matrix and protein-protein interactions as well as structural properties of proteins. Additionally, acidity is a prerequisite for activation of the major gastric enzyme pepsin. Pepsin, produced by gastric chief cells, is secreted into the gastric lumen as the inactive proenzyme pepsinogen [39] . Only at low intragastric pH levels, the prosegment is released making the binding cle available for protein interaction [40] . As pepsin is the rst protein degrading enzyme during gastrointestinal transit, interference with its function has major impact on protein digestion [41] .
Acidity of the chyme has a second main in uence on gastrointestinal protein digestion. Upon arrival in the duodenum, the acidic chyme represents the main stimulus for secretin release by S cells mainly found in the duodenal mucosa ( Fig. 1) [42]. Secretin is essential to stimulate pancreatic secretion of the proteases trypsin, chymotrypsin, and carboxypeptidases [43] . ese proteases and peptidases are responsible for further peptide digestion into single amino acids or small peptides, which are subsequently taken up by enterocytes for nutrition of the human body. Besides its in uence on gastric acidity, the PPI esomeprazole was even demonstrated to induce a signi cant transmucosal leak by compromising the barrier function of the upper gastrointestinal tract already a er ve days of medication [44] . However, in patients with eosinophilic esopha gitis (EoE), mucosal integrity of the esophagus was restored a er high-dose treatment with PPIs in tissue samples from patients with PPI-responsive eosinophilia (PPI-REE) [45] . us, additional studies are needed to evaluate whether anti-ulcer drug intake might be associated not only with compromised digestive capacity of the gastrointestinal tract, but also with a leaky barrier function of the gastrointestinal tract with major implications on health and disease.
Acid suppression medication and the immune response
Already during the rst years a er approval for clinical practice, studies appeared that suggested an in uence of sucralfate on the immune response. Sucralfate was reported to activate the mucosal cyclo oxygenase directly a ecting the arachidonic acid metabolism and leading to elevated synthesis and release of leukotriene C4 [46, 47] . Moreover, an enhanced production of prostaglandins from the gastric mucosa and activation of macrophages were described [48] . Additionally, sucralfate, but also simple antacids are aluminum containing drugs, which might per se exert a substantial in uence on the immune response [49] . Despite common knowledge, the rst focused study evaluating the impact of the aluminum containing drug sucralfate on the immune response appeared in 2007. e authors revealed a T helper cell 2 ( 2) shi a er systemic application in an experimental model and speculated on a possible impact of aluminum on the observed immune response deviation [50] . e biogenic amine histamine exerts an e ect on a large variety of di erent cells including important immune cells via its four receptors [51] . Out of these four, the H2 receptor is not only expressed on gastric parietal cells, but additionally on brain tissue, cardiac tissue, smooth muscle cells, T cells, B cells, and dendritic cells [52] . Especially for dendritic cells, histamine interaction via its H2 receptor was proposed to alter responses to microbial ligands and promote T regulatory cells [51, 53] . Furthermore, it was proposed that H2 receptor activation might shi the immune response towards 2 dominance. us, it is not surprising that H2 receptor antagonists have an eminent e ect on the immune response with an overall immune-activating potential as reviewed by Biswas and colleagues [54] . In context with the above mentioned ndings, it is of special interest that usage of H2 receptor antagonists in in ammatory bowel disease patients was reported to increase the risk for hospitalization [55] .
Also for PPI, a reasonable number of studies report a direct in uence on the immune response unrelated to the inhibition of gastric acid. PPIs were shown to have anti-oxidative e ects in vitro and in vivo [56, 57] . As PPIs interfere with the proton pump, e ects on other, non-gastric cells expressing the H + ,K + -ATPase on extracellular membranes and intracellular organelles like in neutrophils and endothelial cells can be expected [58] . It is known that PPIs decrease expression of intercellular adhesion molecules leading to reduced neutrophil accumulation and inhibited oxidative burst of human neutrophils [59] . Additionally, PPIs were demonstrated to inhibit lysosomal enzymes with broad implication in infectious and tumor immune defense [60] . In contrast, other studies even proposed an association between the intake of PPIs and decreased tumorigenesis, which in some of these studies was beyond the mucosa healing e ect of the drugs [61, 62] . Further more, lansoprazole treatment was described to down-regulate 1 and 2 signaling pathways in the human gastric mucosa [63] and to be associated with decreased levels of proin ammatory cytokines such as interleukin(IL-)6, IL-8 and tumor necrosis factor-(TNF-)α in cultured tracheal epithelial cells [64] . Interestingly, PPIs were also reported to inhibit IL-4 and IL-13 signaling via STAT6 (signal transducer and activator of transcription 6) [65] and in PPI-REE a marked reduction of eotaxin-3, IL-13, IL-5 mRNA expression was observed a er PPI treatment [66] .
Association of anti-ulcer drug intake and allergic reactions
Based on the above reviewed data, it is tempting to speculate that acid-reducing medication might also have an important in uence on the allergic immune response. However, the rst de nitive indication of a correlation between anti-ulcer drug intake and food allergy development was the case history of a patient diagnosed with caviar allergy at our institution [67] . He reported to have been on acid-reducing medication during the rst symptom-free consumption of Beluga caviar. Two years later, he developed severe clinical symptoms including anaphylaxis at the second ingestion of caviar.
Based on this knowledge, we performed experimental studies con rming the correlation of gastric acid-reduction by anti-ulcer drug intake and the development of food allergy irrespective of the type of medication used (i. e., sucralfate, H2-receptor blockers, or PPIs) [68, 69] . e in uence on IgE induction and skewing the immune response towards 2 was con rmed for another subclass of H2 receptor blockers [70] . Furthermore, also less potent acidreducing medication such as antacids and base powder were found to be associated with food allergy development [71] . ese results were con rmed in human studies evaluating the in uence of longterm anti-ulcer drug intake on food sensitization and allergy induction. A cohort of 152 adult patients treated for dyspeptic disorder with either H2 receptor blockers or PPIs was subjected to an allergological screening before and a er a three-month course of acid-reduction treatment. In these patients, we observed a boost of preexisting food-speci c IgE anti bodies in 10 % or de novo IgE formation towards regular constituents of the daily diet in 15 % of all patients. Even though food speci c IgE levels decreased in some patients ve months a er discontinuation of anti-ulcer medication intake, sensitization was still con rmed by positive skin tests [72] . Additionally, food allergy was diagnosed in a patients' subgroup developing hazelnut speci c IgE antibodies during anti-ulcer treatment by doubleblind, placebo-controlled food challenges [68] .
is correlation is not only of importance for adult patients but also for other age groups. Already during pregnancy, acid-suppressing medication represents a risk for maternal food allergy development, but also shi s the immune response of the o -springs towards 2 in an experimental model [73] . ese results were underlined by a population-based birth register study revealing a link between maternal acid suppression therapy during pregnancy and the development of childhood asthma [74] . In line with these data, intake of acidreducing medication during childhood was suggested to be associated with an increased pre valence of food allergy [75, 76] . However, also during immunosenescence in elderly patients gastric acid reduction is a risk for food allergy as indicated by experimental as well as human studies [77, 78] . Moreover, clinical studies revealed impairment of gastric digestion by gastric pH elevation to represent a causative factor for allergic reactions at lower amounts of ingested allergens in already food allergic patients [79, 80] . Not only for food allergy acid-suppressing medication seems to be a risk factor. We additionally reported a correlation between gastric acid suppression and development of IgE-mediated hypersensitivity towards diclofenac [81] . In line with these ndings, a retrospective chart review study reported PPI intake to increase the risk for the development of drug hypersensitivity reactions (DHR) [82] . From this study, no conclusion is possible on the in uence of route of drug administration and drug metabolism on DHR induction during PPI treatment.
Of interest, in a subgroup of patients with EoE, a chronic immune-mediated disorder of the esophagus associated with eosinophilic in ltrates as well as eotaxin and 2 cytokine overexpression, a thera peutic role to PPIs is increasingly accepted [83] . Even though mechanisms are not fully understood and therapeutic applications are controversially discussed [84] , an inhibitory action of PPI on eotaxin 3 expression by blocking STAT6 promotor binding in esophageal cells from patients with EoE was reported [85] . For a better mechanistic understanding, it is of special interest to investigate pathophysiological similarities and di erences between PPI-REE and EoE as well as other 2 driven diseases.
Discussion: Gastric acid reduction and allergy development
e connection between gastric acid reduction and allergy development can be seen in association with several mechanisms of actions or side e ects of these potent drugs.
First of all, acid-suppressing medication substantially interferes with the digestive function of the gastrointestinal tract. A recent study in morbid obese patients undergoing bariatric surgery underlined the important gate-keeping function of gastric digestion in allergy development. e patients' sensitization pro les substantially changed a er elimination of adequate digestion by gastric bypass surgery [86] . Moreover, at least for food allergy induction, resistance of food proteins to gastric digestive enzymes seems to be decisive for allergenicity and has for a long time been regarded as predictive for their sensitizing capacity [41] . Digestion experiments with simu lated gastric uid were even considered to distinguish between potentially allergenic and non-allergenic food compounds and digestion labile food proteins were termed non-sensitizing elicitors [87, 88] . However, during the past decades it has become evident that major food allergens inducing allergic sensitization via the oral route are readily degraded by gastric enzymes under physiological conditions [89] . Especially for these food proteins, interference with the gastrointestinal digestion as it is the case under acid-reducing medication might have major consequences increasing the risk for food allergy develop ment [41] .
Moreover, gastric digestion itself is considered to contribute to tolerance induction via the oral route.
e concept of tolerogenic properties of peptic fragments of food proteins goes back to the late 1970s. At that time, rst studies reported peptic fragments of the model allergen bovine serum albumin (BSA) to be capable of suppressing an antibody response in immunization experiments due to T cell interaction [90, 91] . Pepsin and trypsin digests of certain food allergens might still have retained immunogenic properties of fragments especially with regards to T cell activation [92, 93] . Furthermore, digestion-resistant food proteins might even have an intact IgE binding capacity a er pepsin incubation [94] . Based on this knowledge, experimental trails evaluated pepsinized food protein digests for the development of novel therapeutic approaches in food allergy and demonstrated bene cial e ects on cashew nut and cow's milk allergy [95, 96] . us, hindrance of gastric digestion under anti-ulcer medication might not only increase the sensitization capacity of food proteins by leaving them undigested, but additionally might reduce the availability of tolerogenic digestion fragments.
Another risk factor for allergy induction under acid-reducing medication might be its interference with epithelial barrier function. e integrity of the gastrointestinal epithelium gains increasing attention as dysfunction of the intestinal epithelial barrier is currently discussed as a contributing factor in development and progression of various diseases including food allergy [97, 98] . Interestingly, high levels of total and food-speci c IgE were measured in the gastrointestinal mucosa of peptic ulcer patients, which was discussed as a result of enhanced mucosal permeability in Helicobacter pylori infection [99, 100] . Also for other diseases of the upper gastrointestinal tract such as Barrett's esophagus an increased transepithelial leak was described [101] . In 2008, a rst report appeared linking PPI intake with increased transmucosal leak in the upper gastrointestinal tract [44] . However, in patients with PPI-REE integrity of the esophageal mucosa was restored a er PPI treatment. Due to the di erent outcome in these studies and the lack of information on the in uence of acid suppressive drugs on barrier function of other parts of the gastrointestinal tract, further studies are needed to evaluate a possible contribution to allergy development.
Last but not least, acid suppression drugs might in uence the gastrointestinal microbiome. Gastric acid reduction is known to change the intestinal micro bial composition [102] . On the one hand, PPIs substantially increase the number of bacteria in the oral cavity and the upper gastrointestinal tract due to lack of gastric acidity [103, 104] . On the other hand, PPIs might have an antimicrobial e ect on certain microbes by inhibiting the H + ,K + -ATPase found in bacterial and fungal cell membranes [35, 36] . Microbiome changes during anti-ulcer drug treatment and the known in uence of the intestinal bacterial composition on food allergy [105, 106] could o er a further mechanistic explanation for the observed association between pharmaceutical gastric acid suppression and allergy development. Without any doubt, additional research is needed to in-depth evaluate this possible interaction.
Conclusions and clinical outlook
e functional homeostasis of the gastrointestinal tract is essential for overall immunological health and allergy prevention. Even though treatment with anti-ulcer drugs has an essential health bene t for patients with acid related disorders and is increasingly recognized for treatment of a subset of patients with EoE, it has to be taken into consideration that acid suppression medication substantially interferes with the physiological properties of the gastrointestinal tract. Several mechanisms of action or side e ects of these potent drugs could bene cially or detrimentally in uence ongoing immune responses. So far, experimental as well as clinical studies outlined an association between gastric acid suppression and allergy induction. e causative factors for this correlation probably go beyond the in uence of acid-reducing medication on gastrointestinal protein digestion and might explain the observed variations between patients regarding allergy induction. erefore, prescription of this medication should be based on a clear gastroenterological diagnosis with avoidance of long-term intake, if possible. Additionally, it seems to be crucial to consider the immunological impact of these drugs to ensure full therapeutic bene t and patients' safety. Additional mechanistic studies as well as extensive interdisciplinary exchange are clearly needed and will be essential in the future. 
